Avalo Therapeutics offers an unusually favorable 7.26 risk/reward setup with 109% upside to its take-profit target, but extreme insider selling that failed the engine's insider gate, ongoing cash burn, and overbought near-term momentum argue for caution despite the attractive setup.
Thesis pillars
- Mixed Earnings Elevated Volatility→Stable
- Asymmetric Risk Reward Setup→Stable
- Extreme Insider Selling→Stable
- +2 more pillars — see the Why tab for full reasoning
Avalo Therapeutics, Inc. (AVTX) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality.
Avalo Therapeutics is a clinical-stage biotechnology company developing abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody licensed worldwide from Eli Lilly, as its sole active product candidate for hidradenitis suppurativa (HS). The Phase 2 LOTUS trial completed... Read more
Sell if holding. Engine safety override at $18.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Score 5.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, news events none recent, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: speculative.
About Avalo Therapeutics, Inc.
About Avalo Therapeutics, Inc.
Avalo Therapeutics is advancing abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody licensed worldwide from Eli Lilly, as its sole active product candidate, currently in the Phase 2 LOTUS trial for hidradenitis suppurativa (HS) across sites in the United States, Canada, and ten other countries. The company completed LOTUS enrollment of roughly 250 patients in October 2025 and expects topline data in the second quarter of 2026, with $98.3 million in cash and equivalents at year-end 2025 that it believes funds operations into 2028.
Avalo generates no product revenue and depends on equity offerings, debt, and licensing arrangements to fund operations; it acquired the rights to abdakibart through its first-quarter 2024 acquisition of AlmataBio, which held a worldwide exclusive license from Eli Lilly plus a related agreement with Leap Therapeutics. Under those agreements, Avalo owes Lilly up to $70 million in development and regulatory milestones and up to $650 million in sales milestones, plus royalties of 5% to 15% of net sales, and owes Leap up to $70 million in sales milestones and the former AlmataBio stockholders up to $15 million tied to dosing the first Phase 3 patient. Avalo owns no manufacturing facilities and relies on a single contract development and manufacturing organization (CDMO) to produce clinical supply of abdakibart. The company's composition-of-matter patent for abdakibart expired in February 2026, so Avalo plans to rely primarily on twelve years of U.S. biologics reference-product exclusivity rather than patent protection if the drug is approved.
Show full overview
Avalo's near-term fate rests on a single readout from a single manufacturing source: the 10-K states the company is substantially dependent on the success of abdakibart, having focused its resources on this one lead candidate since acquiring it in March 2024, while relying on just one CDMO to manufacture clinical supply. A delay or negative result from the Phase 2 LOTUS trial, expected to read out in the second quarter of 2026, or a disruption at that single CDMO, would leave Avalo without a second clinical-stage asset to fall back on, and management has already said historical capital constraints have forced it to defer, out-license, or discontinue other programs to protect funding for abdakibart.
See also: Healthcare · Biotechnology
From Avalo Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Avalo Therapeutics, Inc.
Latest news
- NEWS Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38 — benzinga Jul 6, 2026 positive
Generated 2026-07-08T21:03:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineabdakibart (AVTX-009)10-K Item 1A: 'We are substantially dependent on the success of abdakibart (AVTX-009)'
- HIGHSuppliersingle CDMO10-K Item 1: 'We currently rely on a single CDMO to manufacture clinical supply for abdakibart (AVTX-009).'
- HIGHcounterpartyEli Lilly and Company10-K Item 1: 'Abdakibart (AVTX-009) is subject to a world-wide exclusive license from Eli Lilly and Company ("Lilly")'
Material Events(8-K, last 90d)
- 2026-06-23Item 5.02LOWBoard appointed Ron Philip as a director effective June 23, 2026, serving on the Compensation Committee and Science, Development and Commercial Advisory Committee. Routine board appointment, no departure.SEC filing →
- 2026-06-12Item 3.02LOWOn June 11, 2026, Avalo exchanged 4,294.675 shares of Series C preferred stock for new Series C-1 preferred stock with an investor, removing a restriction that had capped that investor's beneficial ownership at 4.99% of common stock, raising it to 9.99%.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Prior stop was $17.36. Score 5.5/10, moderate confidence.
Take-profit target: $39.37 (+110.9% upside). Prior stop was $17.36. Stop-loss: $17.36.
Concentration risk — Pipeline: abdakibart (AVTX-009); Concentration risk — Supplier: single CDMO; Quality below floor (1.8 < 4.0).
Avalo Therapeutics, Inc. trades at a P/E of N/A (forward -7.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover AVTX with a consensus score of 4.4/5. Average price target: $45.
What does Avalo Therapeutics, Inc. do?Avalo Therapeutics is a clinical-stage biotechnology company developing abdakibart (AVTX-009), an anti-IL-1β monoclonal...
Avalo Therapeutics is a clinical-stage biotechnology company developing abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody licensed worldwide from Eli Lilly, as its sole active product candidate for hidradenitis suppurativa (HS). The Phase 2 LOTUS trial completed enrollment in October 2025, with topline data expected in Q2 2026, and Avalo held $98.3 million in cash at year-end 2025, which it believes funds operations into 2028.